Investigation of Peptide-Polymer Interaction in Poly(lactide-co-glycolide) Microspheres (U01)
The summary for the Investigation of Peptide-Polymer Interaction in Poly(lactide-co-glycolide) Microspheres (U01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Food and Drug Administration, which is the U.S. government agency offering this grant.
Investigation of Peptide-Polymer Interaction in Poly(lactide-co-glycolide) Microspheres (U01): Although biodegradable poly(lactide-co-glycolide) (PLGA) polymers have been utilized extensively for the controlled release of peptide drugs, there is still a lack of in-depth understanding of peptide-polymer interaction in PLGA based microspheres. The purpose of the present study is to develop a systematic approach to assess the peptide-polymer interaction in PLGA based microsphere dosage forms. The developed approach should be able to identify the different types of peptide-polymer interactions, characterize and quantify related peptide degradation impurities (e.g., acylation peptide adducts), and determine the formulation parameters, hydration and degradation factors, and manufacturing processes responsible for facilitating peptide-polymer interaction. The results from this study will provide better understanding of peptide-polymer interaction in PLGA based drug delivery systems, which will help the Agency in developing recommendations for evaluation of generic microspheres containing peptide drugs.
|Federal Grant Title:||Investigation of Peptide-Polymer Interaction in Poly(lactide-co-glycolide) Microspheres (U01)|
|Federal Agency Name:||Food and Drug Administration|
|Grant Categories:||Consumer Protection Food and Nutrition Health|
|Type of Opportunity:||Discretionary|
|Funding Opportunity Number:||RFA-FD-16-012|
|Type of Funding:||Cooperative Agreement|
|CFDA Descriptions:||Food and Drug Administration_Research|
|Current Application Deadline:||May 20, 2016|
|Original Application Deadline:||May 20, 2016|
|Posted Date:||Mar 17, 2016|
|Creation Date:||Mar 17, 2016|
|Archive Date:||Jun 19, 2016|
|Total Program Funding:||$250,000|
|Maximum Federal Grant Award:||$250,000|
|Minimum Federal Grant Award:||none|
|Expected Number of Awards:||1|
|Cost Sharing or Matching:||No|
- Applicants Eligible for this Grant
- For profit organizations other than small businesses
Native American tribal organizations (other than Federally recognized tribal governments)
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Independent school districts
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Special district governments
City or township governments
Private institutions of higher education
Public housing authorities/Indian housing authorities
- Additional Information on Eligibility
- Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organization are not eligible to apply.
Foreign components, are not allowed.
- Link to Full Grant Announcement
- Full Announcement of RFA-FD-16-012
- Grant Announcement Contact
- Eric Bozoian
Grants Management Specialist
point of contact
Food and Drug Administration 240-402-7592
- More Grants from the Food and Drug Administration
- • FDA Support for Conferences and Scientific Meetings (R13 Clinical Trial Not Allowed)
- • Drug Development Tools Research Grants (U01 Clinical Trial Not Allowed)
- • Rare Disease Clinical Outcome Assessment Consortium (U01 Clinical Trial Not Allowed)
- • Cigar Tobacco Reference Products Program (UC2) Clinical Trials Not Allowed
- • Implementation of U.S. Food Safety Modernization Act - Identifying, Researching, and Imple...